Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunoprecise Antibodies Ltd (NQ: IPA )

0.9948 -0.0152 (-1.50%)
Streaming Delayed Price Updated: 2:39 PM EDT, Jul 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 41,301
Open 1.020
Bid (Size) 0.9850 (2)
Ask (Size) 0.9947 (1)
Prev. Close 1.010
Today's Range 0.9887 - 1.030
52wk Range 0.9400 - 3.100
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
From ImmunoPrecise Antibodies Ltd.
Via Business Wire

Performance

YTD
-41.48%
-41.48%
1 Month
-10.33%
-10.33%
3 Month
-34.98%
-34.98%
6 Month
-41.48%
-41.48%
1 Year
-67.28%
-67.28%

More News

Read More
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Earnings Outlook For ImmunoPrecise Antibodies
Via Benzinga
BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
EXCLUSIVE: ImmunoPrecise Antibodies' Subsidiary Releases Software With Customizable Interface For AI-Driven Drug Discovery
Via Benzinga
IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
Via ACCESSWIRE
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
Via ACCESSWIRE
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
EXCLUSIVE: Immunoprecise Antibodies and InterSystems Integrate Vector Search With LENSai For AI-Driven Healthcare Applications
Via Benzinga
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA Stock Earnings: ImmunoPrecise Antibodies Misses EPS, Beats Revenue for Q3 2024
Via InvestorPlace
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Earnings Scheduled For March 14, 2024
Via Benzinga
ImmunoPrecise Antibodies (NASDAQ:IPA) Subsidiary BioStrand Introduces Breakthrough AI Model In Life Sciences, Harnessing LLM Stacking And HYFT Technology
Via ACCESSWIRE
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
ImmunoPrecise Antibodies (NASDAQ:IPA) Is Changing How We Look At The Complex World Of Antibody Discovery
Via ACCESSWIRE
ImmunoPrecise Antibodies (NASDAQ: IPA) Is Changing How We Look At The Complex World Of Antibody Discovery
Via Benzinga
ImmunoPrecise Antibodies Reports A 19.9% Revenue Increase As It Launches The Next Phase Of LENSai Portal And SaaS Platforms
Via ACCESSWIRE
ImmunoPrecise Antibodies Reports A 19.9% Revenue Increase As It Launches The Next Phase Of LENSai Portal And SaaS Platforms
Via Benzinga
IPA Stock Earnings: ImmunoPrecise Antibodies Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
IPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.